Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome
protocol for a series of randomized, placebo-controlled N-of-1 trials

Thema's: Begeleiding & behandeling, Gezondheid(szorg), Effectiviteit & implementatie

Onderzoeksprojecten